Polynucleotides treatments
How it works and what to expect
Unlike dermal fillers that add physical volume or hyaluronic acid boosters that deliver hydration, polynucleotide injections work differently. Derived from purified salmon DNA, they are designed to activate your skin's own cellular repair mechanisms rather than temporarily filling or plumping tissue. The result is a gradual, biologically driven improvement in skin quality that builds over weeks and months. At Cosmenon, I introduce all injectable treatments with rigorous clinical oversight and individual patient assessment. Regenerative therapies like polynucleotides are administered within a personalised protocol developed through a thorough consultation, with clinical supervision maintained from the first appointment through to final follow-up.
What polynucleotide injections actually are
From salmon DNA to injectable therapy
Polynucleotides (PN) and their close relative polydeoxyribonucleotide (PDRN) are long-chain DNA fragments purified from salmon sperm or milt. Salmon is chosen for a specific clinical reason: its DNA shares a high degree of biocompatibility with human DNA, making it well-tolerated with very low immunogenicity. The most widely recognised formulation in this category is Rejuran, though several other PN products are used across clinical settings.
It is worth being precise about what these injections are not. They don't add volume. They don't work by hydrating the dermis the way a cross-linked hyaluronic acid filler does. Polynucleotide therapy is a biostimulatory skin treatment, meaning its primary purpose is to trigger the body's own repair processes rather than replace or supplement a structural component.
The cellular mechanism in plain language
After injection into the dermis, PN fragments are broken down into nucleotides. These nucleotides bind to adenosine A2A receptors on fibroblasts, activating what is called the nucleotide salvage pathway. This pathway signals fibroblasts to produce collagen, elastin, and extracellular matrix components, the structural proteins responsible for skin firmness and resilience. Several published studies describe these signalling effects in detail, clarifying the receptor-mediated mechanisms behind PDRN and related polynucleotide therapies. Peer-reviewed research on PDRN mechanisms provides useful context for clinicians and patients alike.
The hydration mechanism runs alongside this. Polynucleotides are hydrophilic polymers, meaning they bind water molecules within the dermis, improving skin barrier function and reducing transepidermal water loss. They also carry an anti-inflammatory effect and stimulate keratinocytes to produce hyaluronic acid naturally. The combined effect of these processes produces improvements in texture, elasticity, and tone that accumulate progressively over four to eight weeks per treatment session.
Who benefits most from polynucleotide skin boosters?
Skin conditions it addresses well
Polynucleotide injections perform best for a specific category of skin concerns: fine lines and surface texture irregularities, crepey or thinning skin, elasticity loss caused by ageing or sun damage, periorbital (under-eye) skin quality decline, and enlarged pores. These are conditions rooted in declining cellular activity, which is precisely where a biostimulatory treatment delivers its strongest value.
Patients recovering from laser treatments or other ablative procedures also benefit from PN therapy. The wound-healing properties of PDRN, including its ability to accelerate epithelialization and support angiogenesis, make it a useful adjunct in post-procedure recovery protocols. Results are gradual and cumulative, not immediate. This treatment suits patients investing in a methodical improvement rather than a dramatic overnight change. For clinicians wanting the primary literature on PDRN's regenerative and wound-healing roles, see published clinical studies documenting these effects. Clinical evidence on PDRN and wound healing.
For readers interested in broader perspectives on biostimulatory approaches, our clinic maintains a set of resources on Skin Biostimulation that explain how these treatments integrate with an overall skin-rejuvenation plan.
Who should approach with caution or avoid treatment?
The primary contraindication is a known allergy to fish or salmon-derived products. Given that polynucleotides are extracted from salmon DNA, patients with this allergy carry a real risk of severe allergic reaction, including anaphylaxis. Active skin infections at the treatment site, autoimmune conditions, immunodeficiency, and active cancer or ongoing chemotherapy are also clear reasons to defer treatment.
Pregnancy and breastfeeding are absolute contraindications due to unknown effects on the fetus or infant. Patients with bleeding disorders or those taking anticoagulant medications require careful assessment before proceeding. A thorough consultation with a qualified medical practitioner, including a full review of health history and current medications, is not optional: it is the baseline standard for safe care.
How polynucleotide treatment compares to PRP, HA boosters, and fillers
Different mechanisms, different outcomes
Understanding how these treatments differ starts with their mechanisms. Traditional HA dermal fillers physically occupy space in the dermis, creating volume and smoothing deep folds. They are reversible with hyaluronidase. HA skin boosters, such as Profhilo, deliver deep hydration and mild biostimulation through non-cross-linked hyaluronic acid. PRP (platelet-rich plasma) uses growth factors concentrated from the patient's own blood to stimulate tissue regeneration. Polynucleotide injections sit closest to PRP in intent, but work through a more specific receptor-binding pathway that targets fibroblast activation directly.
Several studies suggest PN therapy produces superior outcomes to HA options for skin texture, pore size, and elasticity at six to twelve months. The underlying reason is biological: PN drives genuine collagen renewal rather than temporarily filling or hydrating tissue. For patients whose primary concern is skin quality rather than volume, that distinction matters significantly.
Longevity and maintenance compared
HA fillers last approximately six to eighteen months before the body metabolises them. HA skin boosters deliver noticeable hydration but require frequent top-ups to maintain results. PRP outcomes are variable, with improvements in texture and tone that typically last several months but are less predictable in duration. Polynucleotide treatment builds progressively, with the full effect of collagen remodelling becoming visible eight to twelve weeks after the final session of an initial course, and results that can be maintained beyond twelve months with appropriate follow-up care.
One particularly useful clinical rationale is the synergy between PN and HA fillers. Combining polynucleotide therapy with dermal fillers extends overall outcomes by improving the baseline quality of the surrounding skin, making filler results appear more natural and durable. This combination approach is becoming a standard consideration in personalised treatment planning. For clinics offering integrated plans and physician-led protocols, see our information on biostimulator treatments in Melbourne.
Longevity and maintenance compared
HA fillers carry a distinct risk of vascular occlusion, a rare but serious complication that requires immediate medical intervention. Polynucleotide injections carry a far lower risk of vascular occlusion compared with HA fillers, making them a particularly well-suited option for delicate areas like the periorbital zone, though no injectable treatment is entirely without risk. PRP involves a blood draw, adding procedural complexity and patient discomfort. Across all categories, mild side effects including temporary redness, swelling, and bruising are common and resolve within days.
The most significant safety variable across all injectable treatments is not the product itself but the practitioner administering it. A medically qualified provider who assesses the full clinical picture, uses sterile technique, and monitors patient response is the primary factor separating safe, effective outcomes from uncertain ones.
What a typical polynucleotide treatment course looks like
Session numbers, spacing, and the progression of results
Most PN protocols involve three to four initial sessions spaced two to four weeks apart. Initial improvements in skin texture and hydration typically become noticeable around four weeks after treatment begins. The full collagen remodelling effect is visible closer to eight to twelve weeks after the final session in the initial course. After that, maintenance sessions every six to twelve months sustain the result.
The progressive nature of the results reflects the biology of what's happening: genuine fibroblast activation and collagen synthesis take time. I prefer to tailor the exact protocol to each patient's skin condition, age, and treatment goals. There is no single standard prescription; the plan is built around the individual. Session spacing, product dose, and combination with other treatments are all calibrated during the consultation process, not applied as a default template.
Downtime, side effects, and aftercare
Downtime is minimal. Common post-treatment effects include redness, mild swelling, tenderness at injection sites, and occasional small bumps, most of which resolve within one to seven days. Bruising is frequently reported after PN injections but can be reduced with careful technique and appropriate pre-procedure preparation. Serious complications including infection, granuloma formation, and allergic reaction are rare and further minimised by proper sterile technique and thorough pre-treatment screening.
Basic aftercare is simple: avoid touching the treated area in the hours immediately after the procedure, skip intense exercise and heat exposure for twenty-four hours, and apply broad-spectrum SPF consistently throughout the treatment course. Sun protection is not a minor afterthought; it actively protects the collagen being produced during the treatment period. Many patients combine in-clinic treatment with supportive topical care, for example, physician-grade serums and recovery-focused products such as Alastin Skin Nectar, to optimise healing and long-term results.
What the clinical evidence shows and what outcomes are realistic
What peer-reviewed studies actually found
A real-world clinical assessment of sixty-six patients receiving intradermal polynucleotide injections across three sessions found that all facial treatments achieved visible improvement. Over half were rated as "marked" or "excellent" by clinicians, with patient satisfaction rates of 97 to 100% recorded across the cohort. No serious adverse events were reported.
A separate prospective observational study examining the periorbital area specifically demonstrated significant improvements in under-eye wrinkles and crow's feet at the three-month mark following two treatment sessions, with a modest reduction in effect by six months, which supports the rationale for maintenance therapy before that point. Twelve-month follow-up data from broader studies shows sustained improvement in collagen density, skin thickness, and vascularisation, with polynucleotides demonstrating longer duration of action and better outcomes compared to HA fillers at this timeframe for elasticity and skin texture. These are not dramatic single-session transformations. They are consistent, measurable improvements in skin biology that accumulate across a properly structured course of treatment.
Questions worth asking at your consultation
Before committing to any polynucleotide therapy, a well-structured consultation should give you clear answers to the following:
Is this formulation lawfully supplied in Australia, and what is the regulatory basis for its use at this clinic?, information on what regulatory approval means can help you understand supply and advertising standards in Australia:what TGA approval of medicines means.
How many sessions do you recommend for my specific concern, and why?
What should I realistically expect after my first session versus my third?
How does polynucleotide therapy fit alongside any other treatments I'm considering?
What does the aftercare and follow-up process look like at this clinic?
A practitioner who answers these questions with clear, evidence-based responses, and who takes the time for a proper consultation rather than rushing to a treatment decision, is the right clinical environment in which to proceed.
The bottom line on polynucleotide treatment
Polynucleotide treatment is among the most thoroughly studied regenerative injectables for skin quality improvement, supported by multiple clinical studies across diverse patient populations. It works through a fundamentally different mechanism from volume-adding fillers and hydration-focused boosters, activating the skin's own repair processes at a cellular level to produce genuine, lasting improvement. The evidence supports its use for fine lines, texture, elasticity, and periorbital concerns, with a strong safety profile and progressive results that build across a structured initial course.
This is not a quick fix and it is not a dramatic transformation. It is a methodical approach to improving skin from the inside out, grounded in cellular biology and supported by consistent clinical data. The quality of the clinical environment is not a secondary consideration. Doctor-led care, a thorough consultation, and a personalised protocol are what separate a safe, effective outcome from an uncertain one.
If polynucleotide therapy is on your radar, the next step is a medical consultation with a qualified practitioner who can assess your skin, review your health history, and map a plan built specifically around your goals. That is the only way I work: one patient, one plan, full clinical oversight from the first conversation to the final follow-up review.